share_log

Surrozen, Inc. (NASDAQ:SRZN) Short Interest Update

Surrozen, Inc. (NASDAQ:SRZN) Short Interest Update

代理公司（納斯達克：SRZN）短期利息更新
kopsource ·  2023/01/18 09:41

Surrozen, Inc. (NASDAQ:SRZN – Get Rating) was the target of a significant growth in short interest in December. As of December 30th, there was short interest totalling 279,700 shares, a growth of 188.4% from the December 15th total of 97,000 shares. Currently, 1.5% of the shares of the stock are short sold. Based on an average daily trading volume, of 678,900 shares, the days-to-cover ratio is currently 0.4 days.

代羅森公司（NASDAQ：SRZN-獲取評級）是 12 月份短期利益顯著增長的目標。截至 12 月 30 日，短期利息共計 279,700 股，較十二月十五日共 97,000 股股份增長了 188.4%。目前，該股票的 1.5% 股票賣空。根據平均每日交易量為 678,900 股，目前的日期保障比率為 0.4 天。

Surrozen Stock Up 4.5 %

代理股票上升 4.5%

Shares of Surrozen stock opened at $0.65 on Wednesday. The stock has a market cap of $22.75 million, a PE ratio of -0.48 and a beta of -0.24. Surrozen has a 12 month low of $0.34 and a 12 month high of $4.82. The business has a fifty day simple moving average of $0.73 and a 200-day simple moving average of $1.98.

週三股票的股票價格為 0.65 美元。該股的市值為 22.75 萬美元，私募股票比率為 -0.48，貝塔值為 -0.24。代孕有 12 個月低點為 0.34 美元，12 個月高點為 4.82 美元。該業務有 50 天的簡單移動平均線 0.73 美元和 200 天的簡單移動平均線 1.98 美元。

Get
取得
Surrozen
Surrozen
alerts:
警報：

Surrozen (NASDAQ:SRZN – Get Rating) last posted its quarterly earnings results on Monday, November 14th. The company reported ($0.38) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.43) by $0.05. Analysts expect that Surrozen will post -1.46 EPS for the current fiscal year.

代理 (納斯達克:SRZN — 獲取評級) 上次發布了其季度收益業績週一, 11 月 14 日.該公司報告了本季度的每股盈利（0.38 美元），頂部分析師的共識估計（0.43 美元）為 0.05 美元。分析師預計，Surrozen 將在當前財政年度發布 -1.46 每股收益。

Hedge Funds Weigh In On Surrozen

對沖基金權衡托羅

Several institutional investors and hedge funds have recently modified their holdings of SRZN. Bank of Montreal Can purchased a new position in Surrozen in the first quarter valued at about $377,000. FMR LLC bought a new stake in shares of Surrozen in the 2nd quarter valued at approximately $744,000. Vanguard Group Inc. increased its holdings in Surrozen by 3.2% in the third quarter. Vanguard Group Inc. now owns 487,278 shares of the company's stock worth $984,000 after buying an additional 15,299 shares during the last quarter. Finally, Board of Trustees of The Leland Stanford Junior University lifted its stake in Surrozen by 3,102.9% in the third quarter. Board of Trustees of The Leland Stanford Junior University now owns 781,960 shares of the company's stock valued at $1,580,000 after acquiring an additional 757,546 shares during the last quarter. 62.13% of the stock is currently owned by hedge funds and other institutional investors.
幾家機構投資者和對沖基金最近修改了他們對 SRZN 的持有量。蒙特利爾銀行可以在第一季度購買了 Surrozen 的新位置，價值約為 377,000 美元。FMR 有限責任公司在第二季度購買了 Surrozen 股份的新股份，價值約為 744,000 美元。領航集團股份有限公司在第三季度增加了 3.2％ 的股份。領航集團股份有限公司在上一季度額外購買 15,299 股股份後，擁有該公司股票價值 984,000 美元的 487,278 股。最後，利蘭斯坦福初級大學受託人董事會在第三季度將其在 Surrozen 的股份解除了 3,102.9％。利蘭·斯坦福初級大學的受託人董事會現在擁有該公司 781,960 股股票，價值為 1,580,000 美元，在上個季度額外收購 757,546 股。62.13％ 的股票目前由對沖基金和其他機構投資者擁有。

Analysts Set New Price Targets

分析師設定新的價格目標

Several equities analysts have recently issued reports on SRZN shares. Bank of America cut shares of Surrozen from a "neutral" rating to an "underperform" rating in a research note on Wednesday, November 16th. JPMorgan Chase & Co. downgraded Surrozen from a "neutral" rating to an "underweight" rating in a report on Tuesday, November 29th. Finally, Guggenheim downgraded Surrozen from a "buy" rating to a "neutral" rating in a report on Friday, November 18th.

幾位股票分析師最近發布了 SRZN 股票的報告。美國銀行在 11 月 16 日（星期三）的一份研究報告中將 Surrozen 的股票從「中立」評級降至「表現不佳」評級。摩根大通公司在 11 月 29 日（星期二）的一份報告中，代孕從「中立」評級降級為「體重過輕」。最後，在 11 月 18 日（星期五）的一份報告中，古根海姆將代孕從「買入」評級降級為「中性」評級。

Surrozen Company Profile

代理公司簡介

(Get Rating)

(取得評分)

Surrozen, Inc, a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration. It is developing tissue-specific antibodies with application across various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system.

Surrozen, Inc 是一家生物技術公司，發現並開發候選藥物，以選擇性調節 Wnt 組織修復和再生的途徑。它正在開發組織特異性抗體，並應用於各種疾病領域，包括腸道，肝臟，視網膜，角膜，肺，腎，耳蝸，皮膚，胰腺和中樞神經系統的疾病。

Featured Stories

特色故事

  • Get a free copy of the StockNews.com research report on Surrozen (SRZN)
  • J.B. Hunt Gets A Flat, Logistic Companies Come Into Focus
  • Is Intel Stock On The Verge Of Breaking Out?
  • Does it Matter Folks Aren't "Starry-Eyed" Over Pepsi's New Soda?
  • Can Alaska Air Continue Soaring Above The Airline Industry?
  • Johnson & Johnson Breakout Breaks Down: Can Earnings Boost Stock?
  • 獲取有關 Surrozen 的研究報告（SRZN）的免費副本
  • J.B. 亨特得到一個單位, 物流公司成為焦點
  • 英特爾股票是否瀕臨爆發？
  • 這是否重要的人不是「星眼」在百事可樂的新蘇打水?
  • 阿拉斯加航空能否繼續飆升至航空業之上？
  • 約翰遜突破：盈利可以提高股票嗎？

Receive News & Ratings for Surrozen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Surrozen and related companies with MarketBeat.com's FREE daily email newsletter.

接收《Surrozen 日報》的新聞和評分 -在下面輸入您的電子郵件地址，以通過 MarketBeat.com 的免費每日電子郵件通訊接收 Surrozen 及相關公司的最新新聞和分析師評級的簡要每日摘要。

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論